Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Prostatic Neoplasms × lortalamine × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Recurrence 1 Prostatic Neoplasms 1 Neoplasms 1 Disease 1

Interventions

Docetaxel 291 Prednisone 240 enzalutamide 191 Leuprolide 185 Radiotherapy 178 Abiraterone Acetate 169 Magnetic Resonance Spectroscopy 163 bicalutamide 140 Goserelin 138 Androgen Antagonists 119 acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 108 Radiosurgery 108 apalutamide 91 gallium 68 PSMA-11 81 abiraterone 80 Specimen Handling 73 darolutamide 65 Surveys and Questionnaires 64 Gonadotropin-Releasing Hormone 62 Triptorelin Pamoate 58 Radiation 57 Biopsy 57 Brachytherapy 53 cabazitaxel 52 Standard of Care 51 Zoledronic Acid 50 Radiotherapy, Intensity-Modulated 50 pembrolizumab 49 luprolide acetate gel depot 49 Flutamide 47

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02615067 2019-04-10

proSPECT-AS

Molecular Insight Pharmaceuticals, Inc.

Phase 3 Completed

Disease, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡